Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss tariffs on pharmaceuticals, second quarter earnings and outlook ...

Novartis ( NYSE: NVS) CEO Vas Narasimhan said the company has built up its U.S. inventories to help mitigate the impact of ...

Emily Field, head of European pharma research at Barclays, discusses which drug makers would be most impacted by 30% U.S.

Drugmaker Swedish Orphan Biovitrum AB’s Chief Executive Officer Guido Oelkers said he doesn’t think tariff threats on the ...

Johnson and Johnson beat Wall Street’s quarterly sales expectations and raised its full-year outlook, a show of confidence as ...

W hen Donald Trump’s tariffs are mentioned, you might recall his “Liberation Day” duties on uninhabited islands, his on-again ...

A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.

WASHINGTON — Canada likely isn't the main target of U.S. President Donald Trump's threat to impose a 200 per cent tariff on ...

Canadian exports less than 5% of all generic medicines sold in the U.S., but Canada 'could get caught in the crossfire if ...

A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.

President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...

President Donald Trump threatened tariffs of up to 200% on pharmaceuticals imported into the United States — but added that the levies wouldn’t likely be imposed for a year or more.